Center for Devices and Radiological Health Veteran Amputee Devices; Public Workshop; Request for Comments, 68422-68424 [2016-23924]
Download as PDF
68422
Federal Register / Vol. 81, No. 192 / Tuesday, October 4, 2016 / Notices
representatives, employers, and other
parties that provide income to
noncustodial parents.
ANNUAL BURDEN ESTIMATES
Number of
responses per
respondent
Number of
respondents
Instrument
Average
burden hours
per response
Total burden
hours
Income withholding order/notice (Courts, private attorneys, custodial parties
or their representatives).
Income withholding orders/termination of employment/income status (Employers and other income providers).
Electronic income withholding orders/termination of employment/income
status (Employers and other income providers).
3,699,790
1.00
5 minutes .......
308,316
1,207,484
9.694
2 minutes .......
390,178
9,596
136.38
3 seconds ......
1,090
Estimated Total Annual Burden Hours ....................................................
........................
........................
........................
699,585
In compliance with the requirements
of the Paperwork Reduction Act of 1995
(Pub. L. 104–13, 44 U.S.C. Chap 35), the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 330 C Street SW.,
Washington DC 20201. Attn: ACF
Reports Clearance Officer. Email
address: infocollection@acf.hhs.gov. All
requests should be identified by the title
of the information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2016–23865 Filed 10–3–16; 8:45 am]
mstockstill on DSK3G9T082PROD with NOTICES
BILLING CODE 4184–01–P
VerDate Sep<11>2014
19:01 Oct 03, 2016
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
You may submit comments as
follows:
Food and Drug Administration
Electronic Submissions
[Docket No. FDA–2016–N–2655]
Center for Devices and Radiological
Health Veteran Amputee Devices;
Public Workshop; Request for
Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public workshop;
request for comments.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
following public workshop entitled
‘‘Center for Devices and Radiological
Health Veteran Amputee Devices.’’ The
purpose of this workshop is to engage
all stakeholders involved in the
research, development, and marketing
of prosthetic limb medical devices used
by veteran amputees. A specific goal is
to engage veteran amputees who use
prosthetic limb medical devices and
hear their views on these devices so that
these perspectives may be considered in
the total product life cycle of prosthetic
limb devices.
DATES: The public workshop will be
held on October 31, 2016, from 9 a.m.
to 4 p.m. Submit either electronic or
written comments on the public
workshop by November 30, 2016.
ADDRESSES: The public workshop will
be held at FDA’s White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993.
Entrance for the public meeting
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
performed. For parking and security
information, please refer to https://www.
fda.gov/AboutFDA/WorkingatFDA/
BuildingsandFacilities/WhiteOak
CampusInformation/ucm241740.htm.
SUMMARY:
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
E:\FR\FM\04OCN1.SGM
04OCN1
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 192 / Tuesday, October 4, 2016 / Notices
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–2655 for ‘‘Center for Devices
and Radiological Health Veteran
Amputee Devices.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Fabienne Santel, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 3502, Silver Spring,
MD 20993, 301–796–9644, email:
Fabienne.santel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:01 Oct 03, 2016
Jkt 241001
I. Background
The Center for Devices and
Radiological Health (CDRH) is
committed to including views of
patients on the total product life cycle
of medical devices. To better
understand their needs, CDRH plans to
engage patients throughout our
regulatory process. CDRH is interested
in patients contributing their views,
data, and resources to improve the total
product life cycle for medical devices,
reduce adverse events, and improve
communication about the risks and
benefits that matter most to them.
Together with other centers and
offices across FDA, we are testing and
developing ways to engage patients and
capture their views through public
workshops. The CDRH Veteran
Amputee Devices is one such workshop
intended to engage veteran amputees,
such as those patients from the Walter
Reed National Military Medical Center,
Warrior Clinic, who use prosthetic limb
medical devices.
II. Topics for Discussion at the CDRH
Veteran Amputee Devices Public
Workshop
Topics to be discussed at the public
workshop include, but are not limited to
the following:
• Introduce the CDRH Total Product
life Cycle (TPLC) for prosthetic limb
devices.
• A focus group to obtain information
on priorities for upper-limb prosthetics
from the perspective of upper-limb
amputees.
• Presentations from prosthetic limb
device manufacturer.
• Question and answer session where
patients, their caregivers and other
interested parties have an opportunity
to present their views and ask questions
about the total product life cycle of
medical devices.
Registration: Registration is free and
available on a first-come, first-served
basis. Persons interested in attending
the CDRH Veteran Amputee Devices
public workshop must register online by
October 24, 2016. Early registration is
recommended because facilities are
limited and, therefore, FDA may limit
the number of participants from each
organization. If time and space permit,
onsite registration on the day of the
public workshop will be begin at 8 a.m.
If you need special accommodations
due to a disability, please contact Susan
Monahan, Center for Devices and
Radiological Health, Office of
Communication, Education (OCE), 301–
796–5661 email:
Susan.Monahan@fda.hhs.gov no later
than October 17, 2016.
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
68423
To register for the public workshop,
please visit FDA’s Medical Devices
News & Events—Workshops &
Conferences calendar at https://
www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm. (Select this meeting/public
workshop from the posted events list.)
Please provide complete contact
information for each attendee, including
name, title, affiliation, address, email,
and telephone number. Those without
Internet access should contact Fabienne
Santel to register (see FOR FURTHER
INFORMATION CONTACT). Registrants will
receive confirmation after they have
been accepted. You will be notified if
you are on a waiting list.
Streaming Webcast of the Public
Workshop: This public workshop will
also be Webcast. The Webcast link will
be available on the registration Web
page after October 21, 2016.
Organizations are requested to view
using one connection per location. If
you have never attended a Connect Pro
event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. FDA has
verified the Web site addresses in this
document, as of the date this document
publishes in the Federal Register, but
Web sites are subject to change over
time.
Requests for Oral Presentations: This
public workshop includes a public
comment session and topic-focused
sessions. During online registration, you
may indicate if you wish to present
during a public comment session or
participate in a specific session, and
which topics you wish to address. FDA
has included general topics in this
document. FDA will do its best to
accommodate requests to make public
comments or give presentations during
the focused sessions. Individuals and
organizations with common interests are
urged to consolidate or coordinate their
presentations, and request time for a
joint presentation, or submit requests for
designated representatives to participate
in the focused sessions. FDA will
determine the amount of time allotted to
each presenter and the approximate
time each oral presentation is to begin,
and will select and notify participants
by October 17, 2016. All requests to
make oral presentations must be
received by October 10, 2016. If selected
for presentation, any presentation
materials must be emailed to Fabienne
Santel (see FOR FURTHER INFORMATION
CONTACT) no later than October 28, 2016.
If you are a manufacturer and wish to
have a display table, please submit this
E:\FR\FM\04OCN1.SGM
04OCN1
68424
Federal Register / Vol. 81, No. 192 / Tuesday, October 4, 2016 / Notices
request by October 17, 2016. Space is
limited; therefore, FDA will select and
notify manufacturers by October 24,
2016. No commercial or promotional
material will be permitted to be
presented or distributed at the public
workshop.
FDA is holding this public workshop
to obtain views from patients on
prosthetic limb devices so that these
perspectives may be considered in the
total product life cycle of prosthetic
limb medical devices. In order to permit
the widest possible opportunity to
obtain public comment, FDA is
soliciting either electronic or written
comments on all aspects of the public
workshop topics. The deadline for
submitting comments related to this
patient workshop is November 30, 2016.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(see ADDRESSES). A transcript will also
be available in either hardcopy or on
CD–ROM, after submission of a
Freedom of Information request. The
Freedom of Information office address is
available on the Agency’s Web site at
https://www.fda.gov. A link to the
transcripts will also be available
approximately 45 days after the public
workshop on the Internet at https://
www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm. (Select this public
workshop from the posted events list).
Dated: September 26, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–23924 Filed 10–3–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–2976]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Information From
United States Firms and Processors
That Export to the European Union
AGENCY:
Food and Drug Administration,
mstockstill on DSK3G9T082PROD with NOTICES
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
SUMMARY:
VerDate Sep<11>2014
19:01 Oct 03, 2016
Jkt 241001
1995 (the PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on reporting
requirements in implementing the lists
of United States (U.S.) firms/processors
exporting shell eggs, game meat and
game meat products, gelatin, and
collagen to the European Union (the
EU).
DATES: Submit either electronic or
written comments on the collection of
information by December 5, 2016.
ADDRESSES: You may submit comments
as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–2976 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request;
Information From United States Firms
and Processors That Export to the
European Union.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A63, 11601 Landsdown
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\04OCN1.SGM
04OCN1
Agencies
[Federal Register Volume 81, Number 192 (Tuesday, October 4, 2016)]
[Notices]
[Pages 68422-68424]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23924]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-2655]
Center for Devices and Radiological Health Veteran Amputee
Devices; Public Workshop; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
following public workshop entitled ``Center for Devices and
Radiological Health Veteran Amputee Devices.'' The purpose of this
workshop is to engage all stakeholders involved in the research,
development, and marketing of prosthetic limb medical devices used by
veteran amputees. A specific goal is to engage veteran amputees who use
prosthetic limb medical devices and hear their views on these devices
so that these perspectives may be considered in the total product life
cycle of prosthetic limb devices.
DATES: The public workshop will be held on October 31, 2016, from 9
a.m. to 4 p.m. Submit either electronic or written comments on the
public workshop by November 30, 2016.
ADDRESSES: The public workshop will be held at FDA's White Oak Campus,
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993. Entrance for the public meeting
participants (non-FDA employees) is through Building 1 where routine
security check procedures will be performed. For parking and security
information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
[[Page 68423]]
Instructions: All submissions received must include the Docket No.
FDA-2016-N-2655 for ``Center for Devices and Radiological Health
Veteran Amputee Devices.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Fabienne Santel, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 3502, Silver Spring, MD 20993, 301-796-
9644, email: Fabienne.santel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
The Center for Devices and Radiological Health (CDRH) is committed
to including views of patients on the total product life cycle of
medical devices. To better understand their needs, CDRH plans to engage
patients throughout our regulatory process. CDRH is interested in
patients contributing their views, data, and resources to improve the
total product life cycle for medical devices, reduce adverse events,
and improve communication about the risks and benefits that matter most
to them.
Together with other centers and offices across FDA, we are testing
and developing ways to engage patients and capture their views through
public workshops. The CDRH Veteran Amputee Devices is one such workshop
intended to engage veteran amputees, such as those patients from the
Walter Reed National Military Medical Center, Warrior Clinic, who use
prosthetic limb medical devices.
II. Topics for Discussion at the CDRH Veteran Amputee Devices Public
Workshop
Topics to be discussed at the public workshop include, but are not
limited to the following:
Introduce the CDRH Total Product life Cycle (TPLC) for
prosthetic limb devices.
A focus group to obtain information on priorities for
upper-limb prosthetics from the perspective of upper-limb amputees.
Presentations from prosthetic limb device manufacturer.
Question and answer session where patients, their
caregivers and other interested parties have an opportunity to present
their views and ask questions about the total product life cycle of
medical devices.
Registration: Registration is free and available on a first-come,
first-served basis. Persons interested in attending the CDRH Veteran
Amputee Devices public workshop must register online by October 24,
2016. Early registration is recommended because facilities are limited
and, therefore, FDA may limit the number of participants from each
organization. If time and space permit, onsite registration on the day
of the public workshop will be begin at 8 a.m.
If you need special accommodations due to a disability, please
contact Susan Monahan, Center for Devices and Radiological Health,
Office of Communication, Education (OCE), 301-796-5661 email:
Susan.Monahan@fda.hhs.gov no later than October 17, 2016.
To register for the public workshop, please visit FDA's Medical
Devices News & Events--Workshops & Conferences calendar at https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm.
(Select this meeting/public workshop from the posted events list.)
Please provide complete contact information for each attendee,
including name, title, affiliation, address, email, and telephone
number. Those without Internet access should contact Fabienne Santel to
register (see FOR FURTHER INFORMATION CONTACT). Registrants will
receive confirmation after they have been accepted. You will be
notified if you are on a waiting list.
Streaming Webcast of the Public Workshop: This public workshop will
also be Webcast. The Webcast link will be available on the registration
Web page after October 21, 2016. Organizations are requested to view
using one connection per location. If you have never attended a Connect
Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a
quick overview of the Connect Pro program, visit https://www.adobe.com/go/connectpro_overview. FDA has verified the Web site addresses in this
document, as of the date this document publishes in the Federal
Register, but Web sites are subject to change over time.
Requests for Oral Presentations: This public workshop includes a
public comment session and topic-focused sessions. During online
registration, you may indicate if you wish to present during a public
comment session or participate in a specific session, and which topics
you wish to address. FDA has included general topics in this document.
FDA will do its best to accommodate requests to make public comments or
give presentations during the focused sessions. Individuals and
organizations with common interests are urged to consolidate or
coordinate their presentations, and request time for a joint
presentation, or submit requests for designated representatives to
participate in the focused sessions. FDA will determine the amount of
time allotted to each presenter and the approximate time each oral
presentation is to begin, and will select and notify participants by
October 17, 2016. All requests to make oral presentations must be
received by October 10, 2016. If selected for presentation, any
presentation materials must be emailed to Fabienne Santel (see FOR
FURTHER INFORMATION CONTACT) no later than October 28, 2016. If you are
a manufacturer and wish to have a display table, please submit this
[[Page 68424]]
request by October 17, 2016. Space is limited; therefore, FDA will
select and notify manufacturers by October 24, 2016. No commercial or
promotional material will be permitted to be presented or distributed
at the public workshop.
FDA is holding this public workshop to obtain views from patients
on prosthetic limb devices so that these perspectives may be considered
in the total product life cycle of prosthetic limb medical devices. In
order to permit the widest possible opportunity to obtain public
comment, FDA is soliciting either electronic or written comments on all
aspects of the public workshop topics. The deadline for submitting
comments related to this patient workshop is November 30, 2016.
Transcripts: Please be advised that as soon as a transcript is
available, it will be accessible at https://www.regulations.gov. It may
be viewed at the Division of Dockets Management (see ADDRESSES). A
transcript will also be available in either hardcopy or on CD-ROM,
after submission of a Freedom of Information request. The Freedom of
Information office address is available on the Agency's Web site at
https://www.fda.gov. A link to the transcripts will also be available
approximately 45 days after the public workshop on the Internet at
https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. (Select this public workshop from the posted events list).
Dated: September 26, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-23924 Filed 10-3-16; 8:45 am]
BILLING CODE 4164-01-P